Dr. Siefker-Radtke on FDA Approval of Avelumab in Bladder Cancer

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of avelumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed after platinum-based therapy.

Related Content:

The University of Texas MD Anderson Cancer CenterOncLive TVImmuno-OncologyGenitourinary CancersImmunotherapy in GU Cancers
Liao Emphasizes the Importance of Multidisciplinary Collaboration in HCC
Liao Highlights Treatment Selection Considerations and Key Data in Biliary Tract Cancer
Dr Wirth on the LIBRETTO-001 Trial of Selpercatinib in RET Fusion+ Thyroid Cancer